Loading
A phase 3 trial of an investigational treatment in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC is a phase 3 interventional study registered as NCT06569420 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 275 participants enrolled, started 2021-12-31 and due to reach its primary completion in 2025-07-31.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.